EATG » Hepatitis

Hepatitis

Harvoni produces high SVR rates in real-world cohort of veterans

In a real-world cohort of veterans with hepatitis C virus infection genotype 1, Harvoni-based therapy produced sustained virologic response rates over 90%, according to published findings. “HCV disproportionately affects the…

Ireland to expand hepatitis C treatment programme

An estimated 20,000 to 50,000 people in Ireland chronically infected with the disease Anti-viral drugs that can cure Hepatitis C are to be provided to an additional 1,500 people with…

Ribavirin levels too high or low in most patients taking DAAs

Most HCV patients in a 100-person Netherlands analysis had ribavirin concentrations above or below the target range when taking the drug with direct-acting antivirals (DAAs) . Ribavirin starting doses appeared…

Race does not impact early mortality among patients with chronic HCV

Recent findings published in the Journal of Viral Hepatitis showed that race was a nonfactor in the early mortality of patients with hepatitis C virus infection. African-American patients with kidney disease and…

Alcohol, not marijuana, linked to liver injury in women with both HIV and hepatitis C

Hepatitis C virus (HCV) infects the liver and can cause inflammation. If the infection becomes chronic, the struggle between the virus and the immune system results in healthy liver tissue…

France to provide universal access to hepatitis C treatment

France will provide access to hepatitis C treatment with direct-acting antivirals to everyone diagnosed with hepatitis C from September 2016, and will begin to provide treatment to everyone with stage…

ContraVir initiates head-to-head Phase 2a clinical study of CMX157 vs. Viread® for treating hepatitis B

First study to evaluate the antiviral power of CMX157 compared to the current standard of care in hepatitis B EDISON, N.J., June 1, 2016 -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV),…

Burden of pricey hepatitis C drugs heaviest in Eastern Europe

May 31, 2016 - New hepatitis C drugs that can cure the liver-destroying disease are revolutionizing treatment but their high price is a huge burden in some countries, particularly in…

ContraVir to expand hepatitis B portfolio through strategic merger agreement with Ciclofilin Pharmaceuticals

EDISON, N.J., May 31, 2016 -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has entered into…

World Health Assembly adopts global health sector strategies on HIV, viral hepatitis and STIs

The World Health Assembly, held on 23-28 May, has adopted 3 global health sector strategies on: HIV,viral hepatitis and sexually transmitted infections(STIs) for the period 2016-2021. The integrated strategies highlight…